Dr. Barr on Temozolomide and Capecitabine in Neuroendocrine Tumors

Jodie Barr, DO
Published: Monday, Jul 16, 2018



Jodie Barr, DO, hematologist/oncologist, Lawrence Memorial Hospital, discusses the combination of temozolomide and capecitabine in neuroendocrine tumors (NETs).

Findings of small studies have confirmed the efficacy of combination therapy with capecitabine and temozolomide. Data from NYU Langone Health has suggested that the combination has an important cell-directed cycle effect on tumor cells.

In a study that examined the combination, patients were randomized to either temozolomide and capecitabine or temozolomide. The rationale stemmed from capecitabine’s potential synergistic effect with temozolomide in depleting O6-Methylguanine-DNA methyltransferase, says Barr.

The trial enrolled patients with grade 1/2 disease. The study was not blinded, which served as a bias of the study. Investigators examined progression-free survival (PFS) as the primary endpoint and found a significant benefit in PFS with capecitabine and temozolomide. The interim analysis showed hints of benefit in overall survival as well, says Barr.

Although its efficacy has been proven in a number of small studies, the combination regimen is more complex. Patients must take 1 of the drugs 2 out of the 4 weeks and the other drug every 10 to 14 days.


Jodie Barr, DO, hematologist/oncologist, Lawrence Memorial Hospital, discusses the combination of temozolomide and capecitabine in neuroendocrine tumors (NETs).

Findings of small studies have confirmed the efficacy of combination therapy with capecitabine and temozolomide. Data from NYU Langone Health has suggested that the combination has an important cell-directed cycle effect on tumor cells.

In a study that examined the combination, patients were randomized to either temozolomide and capecitabine or temozolomide. The rationale stemmed from capecitabine’s potential synergistic effect with temozolomide in depleting O6-Methylguanine-DNA methyltransferase, says Barr.

The trial enrolled patients with grade 1/2 disease. The study was not blinded, which served as a bias of the study. Investigators examined progression-free survival (PFS) as the primary endpoint and found a significant benefit in PFS with capecitabine and temozolomide. The interim analysis showed hints of benefit in overall survival as well, says Barr.

Although its efficacy has been proven in a number of small studies, the combination regimen is more complex. Patients must take 1 of the drugs 2 out of the 4 weeks and the other drug every 10 to 14 days.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x